Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory ...
New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of ...
Actuate Announces Scientific Reports Publication On Elraglusib’S Novel Immunomodulatory ...
New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the <a target=_blank href=https ...
Actuate获得FDA孤儿药资格认定用于癌症治疗
芝加哥和德克萨斯州沃思堡 - 临床阶段生物制药公司Actuate Therapeutics, Inc. (NASDAQ: ACTU)宣布,美国食品和药物管理局(FDA)已授予其研究性药物elraglusib用于软组织肉瘤(STS)治疗的孤儿药资格认定(ODD)。这一认定是elraglusib的重要里程碑,该药物是一种新型的糖原合成酶激酶-3β(GSK-3β)抑制剂,GSK-3β是一种参与肿瘤生长和 ...
Nasdaq12 天
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue ...
CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
Actuate Gets FDA Orphan Designation for Elraglusib in Soft Tissue Sarcomas
Fort Worth, Texas, clinical-stage biopharmaceutical company Actuate said elraglusib has shown a favorable safety profile and antitumor activity across several solid tumors, including melanoma, Ewing ...
Nasdaq1 个月
Actuate Therapeutics, Inc. Common stock (ACTU) Real-Time
Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.
CNN1 个月
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue ...
Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate ...
Yahoo Finance1 个月
Actuate Therapeutics Announces Closing of Initial Public Offering
CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing ...
Investing13 天
Actuate gains FDA orphan drug status for cancer treatment
CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug ...
Investing13 天
Actuate gains FDA orphan drug status for cancer treatment
CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug ...
Razer just added its banned Snap Tap feature to all its recent laptops and keyboards
Razer notes that Snap Tap may not be as effective with just any Razer laptop or desktop keyboard. It’s best in combination ...